Ind-Swift Laboratories Limited (INDSWFTLAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ind-Swift Laboratories Limited (INDSWFTLAB) has a cash flow conversion efficiency ratio of -0.015x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs-202.50 Million ≈ $-2.19 Million USD) by net assets (Rs13.07 Billion ≈ $141.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ind-Swift Laboratories Limited - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Ind-Swift Laboratories Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Ind-Swift Laboratories Limited balance sheet liabilities for a breakdown of total debt and financial obligations.
Ind-Swift Laboratories Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ind-Swift Laboratories Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Arihant Superstructures Limited
NSE:ARIHANTSUP
|
-0.225x |
|
Korea Computer & Systems Inc
KQ:115500
|
-0.094x |
|
Gambling.com Group Ltd
NASDAQ:GAMB
|
-0.114x |
|
Rawlplug S.A.
WAR:RWL
|
0.070x |
|
Kutahya Seker Fabrikasi AS
IS:KTSKR
|
-0.005x |
|
Cheops Technology France SA
PA:MLCHE
|
N/A |
|
ParTec AG
XETRA:JY0
|
N/A |
|
AB VILKUSKIU PIEN.EO 029
F:UDW
|
N/A |
Annual Cash Flow Conversion Efficiency for Ind-Swift Laboratories Limited (2006–2025)
The table below shows the annual cash flow conversion efficiency of Ind-Swift Laboratories Limited from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Ind-Swift Laboratories Limited worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs11.73 Billion ≈ $126.85 Million |
Rs-254.74 Million ≈ $-2.75 Million |
-0.022x | +89.19% |
| 2024-03-31 | Rs8.12 Billion ≈ $87.82 Million |
Rs-1.63 Billion ≈ $-17.64 Million |
-0.201x | -170.38% |
| 2023-03-31 | Rs6.82 Billion ≈ $73.75 Million |
Rs1.95 Billion ≈ $21.05 Million |
0.285x | +14.11% |
| 2022-03-31 | Rs6.01 Billion ≈ $64.98 Million |
Rs1.50 Billion ≈ $16.25 Million |
0.250x | +11.83% |
| 2021-03-31 | Rs6.03 Billion ≈ $65.26 Million |
Rs1.35 Billion ≈ $14.59 Million |
0.224x | +14.40% |
| 2020-03-31 | Rs6.41 Billion ≈ $69.28 Million |
Rs1.25 Billion ≈ $13.54 Million |
0.195x | +278.44% |
| 2019-03-31 | Rs5.88 Billion ≈ $63.57 Million |
Rs-644.00 Million ≈ $-6.96 Million |
-0.110x | -182.93% |
| 2018-03-31 | Rs5.53 Billion ≈ $59.83 Million |
Rs730.90 Million ≈ $7.90 Million |
0.132x | -26.55% |
| 2017-03-31 | Rs5.31 Billion ≈ $57.46 Million |
Rs955.66 Million ≈ $10.34 Million |
0.180x | +17.17% |
| 2016-03-31 | Rs5.17 Billion ≈ $55.96 Million |
Rs794.30 Million ≈ $8.59 Million |
0.154x | -7.25% |
| 2015-03-31 | Rs5.95 Billion ≈ $64.30 Million |
Rs983.98 Million ≈ $10.64 Million |
0.166x | +83.17% |
| 2014-03-31 | Rs7.25 Billion ≈ $78.43 Million |
Rs655.29 Million ≈ $7.09 Million |
0.090x | +265.47% |
| 2013-03-31 | Rs8.53 Billion ≈ $92.30 Million |
Rs-466.03 Million ≈ $-5.04 Million |
-0.055x | -161.11% |
| 2012-03-31 | Rs8.12 Billion ≈ $87.78 Million |
Rs725.24 Million ≈ $7.84 Million |
0.089x | +193.19% |
| 2011-03-31 | Rs5.84 Billion ≈ $63.10 Million |
Rs177.83 Million ≈ $1.92 Million |
0.030x | -69.08% |
| 2010-03-31 | Rs4.48 Billion ≈ $48.48 Million |
Rs441.84 Million ≈ $4.78 Million |
0.099x | -64.25% |
| 2009-03-31 | Rs3.63 Billion ≈ $39.27 Million |
Rs1.00 Billion ≈ $10.83 Million |
0.276x | +61.91% |
| 2008-03-31 | Rs3.33 Billion ≈ $36.06 Million |
Rs567.77 Million ≈ $6.14 Million |
0.170x | +17.18% |
| 2007-03-31 | Rs3.11 Billion ≈ $33.68 Million |
Rs452.62 Million ≈ $4.89 Million |
0.145x | +137.58% |
| 2006-03-31 | Rs1.92 Billion ≈ $20.80 Million |
Rs117.63 Million ≈ $1.27 Million |
0.061x | -- |
About Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hy… Read more